London, UK – 31 October, 2008: Onyvax Limited, the biotechnology company developing novel cancer therapies, today announced that, in collaboration with the John van Geest Cancer Research Centre (based at Nottingham Trent University, Nottingham UK), researchers have discovered an immunological profile that could be used to predict whether a patient will respond to cancer vaccine therapy. If validated, this profile could be used to streamline the development of cancer vaccines by targeting those patients who may be more likely to respond to the therapy. The data was published on 30 October 2008 at the second ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer in Hollywood, Florida.
